Core Insights - Guoyi Tong (Beijing) Technology Development Co., Ltd. has completed nearly 100 million yuan in Series D financing, led exclusively by Zhejiang Shengxie Health Fund [1] - The funds raised will primarily be used for the development of core research products, commercialization promotion, and the construction of new production lines [1] Company Overview - Since 2016, the company has focused on blood purification products and technology services, providing a comprehensive solution of "equipment + consumables + chronic disease management + medical services" for medical institutions and kidney disease patients [1] - The company's product business has covered over a thousand medical institutions, with a steadily increasing proportion of grassroots institutions, highlighting its leading advantage in the grassroots dialysis center market [1] Market Positioning - The company aligns well with the hierarchical diagnosis and treatment policy, effectively addressing the pain points of grassroots dialysis centers in terms of professional capability, operational efficiency, and talent shortages [1] Product Development - Guoyi Tong has established a closed-loop development model of "service empowering industrial innovation, industrial empowering service quality improvement," forming a rich product matrix including water treatment systems for hemodialysis, centralized liquid supply equipment, dialysis concentrates, and dialysis devices [1] - The company continues to promote technological breakthroughs and innovative research, developing key products such as peritonitis prediction systems (patented in the US, EU, and China), high and ultra-high permeability dialysis devices, peritoneal dialysis solutions, CRRT equipment, and related consumables [1] Strategic Growth - The company is also focusing on mergers and acquisitions in the blood purification industry to accelerate the comprehensive coverage of its blood purification product system, extending the entire chain and upgrading to intelligent solutions [1]